Shopping Cart
- Remove All
Your shopping cart is currently empty
Bortezomib-pinanediol
🥰Excellent
Catalog No. T7854Cas No. 205393-22-2
Bortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib.
Bortezomib-pinanediol
🥰Excellent
Purity: 97.5%
Catalog No. T7854Cas No. 205393-22-2
Bortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | 93 € | In Stock | |
| 2 mg | 138 € | In Stock | |
| 5 mg | 200 € | In Stock | |
| 10 mg | 316 € | In Stock | |
| 25 mg | 567 € | In Stock | |
| 50 mg | 809 € | In Stock | |
| 100 mg | 1.111 € | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "Bortezomib-pinanediol"
4'-Hydroxychalcone
2-Benzal-4-Hydroxyacetophenone
T79172657-25-2
4'-Hydroxychalcone (2-Benzal-4-Hydroxyacetophenone) is a chalcone metabolite with hepatoprotective activity
- 44 €
Size
QTY
Sitagliptin
Cited
MK0431
T0242486460-32-6
Sitagliptin (MK0431), a new oral hypoglycemic (anti-diabetic drug), is a new dipeptidyl peptidase-4 (DPP-4) inhibitor. This enzyme-inhibiting drug is used either alone or in combination with metformin or thiazolidinedione for treatment of type 2 diabetes mellitus. The drug can competitively inhibit a protein/enzyme and DPP-4, that leads to an incremental amount of active incretins (GLP-1 and GIP), the diminished amount of release of glucagon and increased release of insulin.
- 34 €
Size
QTY
CitedVildagliptin Cited
NVP-LAF 237, LAF237
T1502274901-16-5
Vildagliptin (LAF237) is a cyanopyrrolidine-based, orally bioavailable inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity. Vildagliptin's cyano moiety undergoes hydrolysis and this inactive metabolite is excreted mainly via the urine.
- 37 €
Size
QTY
CitedSitagliptin phosphate monohydrate
MK-0431 phosphate monohydrate, MK-0431
T0242L654671-77-9
Sitagliptin phosphate monohydrate (MK-0431 phosphate monohydrate) is a potent DPP-IV inhibitor with an IC50 of 19 nM in Caco-2 cell extracts.
- 47 €
Size
QTY
Linagliptin
BI 1356
T0191668270-12-0
Linagliptin (BI 1356) is a potent, orally bioavailable dihydropurinedione-based inhibitor of dipeptidyl peptidase 4 (DPP-4), with hypoglycemic activity.
- 36 €
Size
QTY
Alloxan monohydrate
T78142244-11-3
Alloxan Monohydrate is a glucose analog used to induce diabetes by destroying beta-cells.
- 27 €
Size
QTY
Teneligliptin hydrobromide
MP-513 (hydrobromide)
T6999906093-29-6
Teneligliptin hydrobromide (MP-513 (hydrobromide)) is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.
- 29 €
Size
QTY
Anagliptin
SK-0403
T7133739366-20-2
Anagliptin (SK-0403) is a potent inhibitor of DPP-4 (IC50 of 3.8 nM) used in the treatment of type 2 diabetes mellitus.
- 37 €
Size
QTY
Bortezomib
Cited
Radiciol, NSC 681239, MG 341, LDP 341, DPBA, Brotezamide
T2399179324-69-7
Bortezomib (LDP 341) is a 20S proteasome inhibitor (Ki=0.6 nM) that is reversible and selective. Bortezomib has antitumor activity and inhibits NF-κB, which can disrupt the cell cycle and induce apoptosis.
- 45 €
Size
QTY
CitedAprotinin Cited
Traskolan, Bovine Pancreatic Trypsin Inhibitor, Antilysin
T33599087-70-1
Aprotinin (Traskolan) is a broad-spectrum serine protease (BPTI) inhibitor that inhibits the activity of a number of different esterases and proteases. Aprotinin is an antifibrinolytic agent used to minimize hemorrhage during complex surgical procedures.
- 37 €
Size
QTY
CitedTCH-165
T170111446350-60-2
TCH-165 is a small molecule modulator of proteasome assembly, resulting in an increase in 20S levels. The increase in the level of free 20S corresponds to enhanced proteolysis of IDPs.
- 64 €
Size
QTY
(R)-MG-132
Z-Leu-D-leu-leu-al, (S,R,S)-(-)-MG-132
T126281211877-36-9
(R)-MG-132 (Z-Leu-D-leu-leu-al) is the enantiomer of MG-132.
- 32 €
Size
QTY
Select Batch
Purity:97.5%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | Bortezomib-pinanediol is a proteasome inhibitor. is a prodrug of Bortezomib. |
| In vivo | Bortezomib-pinanediol (BP)-loaded HA-CCMs exhibit markedly enhanced toleration, broadened therapeutic window, and significantly more effective growth suppression of CD44-overexpressed multiple myeloma in nude mice than free bortezomib.?Lipophilized BTZ-loaded HA-CCMs has opened a new avenue for targeted bortezomib therapy of multiple myeloma. |
| Molecular Weight | 518.46 |
| Formula | C29H39BN4O4 |
| Cas No. | 205393-22-2 |
| Smiles | [H][C@@]12C[C@@]([H])(C1(C)C)[C@]1(C)OB(O[C@]1([H])C2)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1 |
| Relative Density. | 1.19 g/cm3 |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||
| Solubility Information | DMSO: 2.87 mg/mL (5.53 mM)  | |||||||||||||||
Solution Preparation Table | ||||||||||||||||
DMSO
| ||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Bortezomib-pinanediol | purchase Bortezomib-pinanediol | Bortezomib-pinanediol cost | order Bortezomib-pinanediol | Bortezomib-pinanediol chemical structure | Bortezomib-pinanediol in vivo | Bortezomib-pinanediol formula | Bortezomib-pinanediol molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.